William Levin, MD
University of Pennsylvania Cancer Center
Last Modified: November 6, 2001
Presenter: A. Pollack
Presenter's Affiliation: UT MD Anderson Cancer Center, Houston, TX
Type of Session: Scientific
Abnormal expression of certain proteins have been found to alter the normal process of dying, or apoptosis, in cells. To date, there is little data correlating the presence of these proteins with outcome after radiation therapy for prostate cancer. This study looks at the relationship between the expression of Ki-67, Bcl-2, Bax, and bcl-x from pretreatment biopsy specimens and patient outcome after definitive radiotherapy alone.
Abnormal expression of Bcl-2 and Bax is correlated with increased failure after external beam radiotherapy. Bax overexpression and underexpression are both correlated with biochemical failure. Increased expression of KI 67 also is predictive of poor outcome.
In the future, screening pre-treatment tissue samples for expression of certain proteins might help identify patients at high risk for treatment failure. This information could be used when choosing therapy and when designing clinical trials.
Oncolink's ASTRO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology and Pharmacia Oncology.
Aug 31, 2011 - BCL2L1 is involved in several colorectal cancer-related processes and its protein expression is associated with chromosome 20q gain, according to a study published online Aug. 18 in The Journal of Pathology.